Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles P Hart

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Drug Discovery Today|April 6, 2005
Finding the target after screening the phenotypeCharles P Hart
Tomography (Ann Arbor, Mich.)|October 19, 2016
Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma ModelsAshley M Stokes, Charles P Hart, C Chad Quarles
Environmental Science & Technology|May 21, 2009
Geochemistry of inorganic nitrogen in waters released from coal-bed natural gas production wells in the Powder River Basin, WyomingRichard L Smith, Deborah A Repert, Charles P Hart
Cancer Chemotherapy and Pharmacology|July 20, 2007
A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activityFanying Meng, Xiaohong Cai, Jianxin Duan, et al.
Anti-Cancer Drugs|March 14, 2007
ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1alpha accumulationFanying Meng, Xuan-Thao Nguyen, Xiaohong Cai, et al.
BMC Cancer|May 22, 2015
Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibitionFanying Meng, Deepthi Bhupathi, Jessica D Sun, et al.
Antioxidants & Redox Signaling|July 26, 2017
Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo StudiesYoichi Takakusagi, Shun Kishimoto, Sarwat Naz, et al.
Plos One|May 27, 2016
MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer XenograftsXiaomeng Zhang, Jonathan W Wojtkowiak, Gary V Martinez, et al.
Cancer Biology & Therapy|January 29, 2016
Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer modelsJessica D Sun, Qian Liu, Dharmendra Ahluwalia, et al.
Oncotarget|February 8, 2024
Retraction: Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapyChanghwan Yoon, Kevin K Chang, Jun Ho Lee, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Drug Discovery Today|April 6, 2005
Finding the target after screening the phenotypeCharles P Hart
Tomography (Ann Arbor, Mich.)|October 19, 2016
Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma ModelsAshley M Stokes, Charles P Hart, C Chad Quarles
Environmental Science & Technology|May 21, 2009
Geochemistry of inorganic nitrogen in waters released from coal-bed natural gas production wells in the Powder River Basin, WyomingRichard L Smith, Deborah A Repert, Charles P Hart
Cancer Chemotherapy and Pharmacology|July 20, 2007
A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activityFanying Meng, Xiaohong Cai, Jianxin Duan, et al.
Anti-Cancer Drugs|March 14, 2007
ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1alpha accumulationFanying Meng, Xuan-Thao Nguyen, Xiaohong Cai, et al.
BMC Cancer|May 22, 2015
Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibitionFanying Meng, Deepthi Bhupathi, Jessica D Sun, et al.
Antioxidants & Redox Signaling|July 26, 2017
Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo StudiesYoichi Takakusagi, Shun Kishimoto, Sarwat Naz, et al.
Plos One|May 27, 2016
MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer XenograftsXiaomeng Zhang, Jonathan W Wojtkowiak, Gary V Martinez, et al.
Cancer Biology & Therapy|January 29, 2016
Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer modelsJessica D Sun, Qian Liu, Dharmendra Ahluwalia, et al.
Oncotarget|February 8, 2024
Retraction: Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapyChanghwan Yoon, Kevin K Chang, Jun Ho Lee, et al.
Pageof 4